Amyloid β oligomers decrease hippocampal spontaneous network activity in an age-dependent manner

Current Alzheimer Research

Volumn 7, Issue 5, 2010, Pages 453-462

  Balleza Tapia, H ^a   Huanosta Gutierrez A ^a   Marquez Ramos A ^a   Arias, N ^a   Pena F ^a  

^a DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

Age; Alzheimer's disease; Amyloid oligomers; Hippocampal spontaneous activity

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; LACTATE DEHYDROGENASE;

AGE; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ARTICLE; BRAIN FUNCTION; CELL DEATH; CONTROLLED STUDY; DOSE RESPONSE; ENZYME RELEASE; HIPPOCAMPUS; IC 50; MOUSE; NEWBORN; NONHUMAN; PRESYNAPTIC NERVE; PRIORITY JOURNAL; SYNAPTIC POTENTIAL; SYNAPTIC TRANSMISSION;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANIMALS, NEWBORN; HIPPOCAMPUS; INHIBITORY CONCENTRATION 50; MICE; NERVE NET; NEURAL INHIBITION; PEPTIDE FRAGMENTS; SYNAPTIC TRANSMISSION;

EID: 78549243744     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720510791383859     Document Type: Article

References (91)

1. Peña F, Gutierrez-Lerma A, Quiroz-Baez R, Arias C. The role of beta-amyloid protein in synaptic function: implications for Alzheimer's Disease Therapy. Curr Neuropharmacol 4(2): 149-163 (2006).
2. Selkoe DJ. Aging, amyloid, and Alzheimer's disease: a perspective in honor of Carl Cotman. Neurochem Res 28(11): 1705-1713 (2003).
3. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30(4): 572-580 (1991).
4. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 155(3): 853-862 (1999).
5. Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, et al. Correlation between elevated levels of amyloid beta- peptide in the brain and cognitive decline. JAMA 283(12): 1571-1577 (2000).
6. Giacchino J, Criado JR, Games D, Henriksen S. In vivo synaptic transmission in young and aged amyloid precursor protein transgenic mice. Brain Res 876(1-2): 185-190 (2000).
7. Hsia AY, Masliah E, McConlogue L, Yu GQ, Tatsuno G, Hu K, et al. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc Natl Acad Sci USA 96(6): 3228-3233 (1999).
8. Moechars D, Dewachter I, Lorent K, Reverse D, Baekelandt V, Naidu A, et al. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem 274(10): 6483-6492 (1999).
9. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, et al. High-level neuronal expression of a beta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 20(11): 4050-4058 (2000).
10. Stephan A, Laroche S, Davis S. Generation of aggregated beta- amyloid in the rat hippocampus impairs synaptic transmission and plasticity and causes memory deficits. J Neurosci 21(15): 5703-5714 (2001).
11. Peña F, Ordaz B, Balleza-Tapia H, Bernal-Pedraza R, Márquez- Ramos A, Carmona-Aparicio L, et al. Beta-amyloid protein (25-35) disrupts hippocampal network activity: role of Fynkinase. Hippo- campus 20(1): 78-96 (2010).
12. Small DH. Network dysfunction in Alzheimer's disease: does synaptic scaling drive disease progression? Trends Mol Med 14(3): 103-108 (2008).
13. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, et al. Diffusible, nonfibrillar ligands derived from Abeta 1- 42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95(11): 6448-6453 (1998).
14. Rowan MJ, Klyubin I, Wang Q, Anwyl R. Mechanisms of the inhibitory effects of amyloid beta-protein on synaptic plasticity. Exp Gerontol 39(11-12): 1661-1667 (2004).
15. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416(6880): 535-539 (2002).
16. Wang HW, Pasternak JF, Kuo H, Ristic H, Lambert MP, Chromy B, et al. Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res 924(2): 133-140 (2002).
17. Wang Q, Rowan MJ, Anwyl R. Beta-amyloid-mediated inhibition of NMDA receptor-dependent long-term potentiation induction in- volves activation of microglia and stimulation of inducible nitric oxide synthase and superoxide. J Neurosci 24(27): 6049-6056 (2004).
18. Wang Q, Walsh DM, Rowan MJ, Selkoe DJ, Anwyl R. Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J Neurosci 24(13): 3370-3378 (2004).
19. Driver JE, Racca C, Cunningham MO, Towers SK, Davies CH, Whittington MA, et al. Impairment of hippocampal gamma- frequency oscillations in vitro in mice overexpressing human amyloid precursor protein (APP). Eur J Neurosci 26(5): 1280-1288 (2007).
20. Sun MK, Alkon DL. Impairment of hippocampal CA1 heterosynaptic transformation and spatial memory by beta-amyloid(25-35). J Neurophysiol 87(5): 2441-2449 (2002).
21. Cacucci F, Yi M, Wills TJ, Chapman P, O'Keefe J. Place cell firing correlates with memory deficits and amyloid plaque burden in Tg2576 Alzheimer mouse model. Proc Natl Acad Sci USA 105(22): 7863-7868 (2008).
22. Fonte J, Miklossy J, Atwood C, Martins R. The severity of cortical Alzheimer's type changes is positively correlated with increased amyloid-beta Levels: Resolubilization of amyloid-beta with transition metal ion chelators. J Alzheimers Dis 3(2): 209-219 (2001).
23. Kuo YM, Emmerling MR, Bisgaier CL, Essenburg AD, Lampert HC, Drumm D, et al. Elevated low-density lipoprotein in Alzheimer's disease correlates with brain abeta 1-42 levels. Biochem Biophys Res Commun 252(3): 711-715 (1998).
24. Patel JR, Brewer GJ. Age-related changes to tumor necrosis factor receptors affect neuron survival in the presence of beta-amyloid. J Neurosci Res 86(10): 2303-2313 (2008).
25. Shinkai Y, Yoshimura M, Morishima-Kawashima M, Ito Y, Shimada H, Yanagisawa K, et al. Amyloid beta-protein deposition in the leptomeninges and cerebral cortex. Ann Neurol 42(6): 899-908 (1997).
26. Wang J, Dickson DW, Trojanowski JQ, Lee VM. The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol 158(2): 328-337 (1999).
27. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 8(1): 79-84 (2005).
28. Liu Q, Huang Y, Xue F, Simard A, DeChon J, Li G, et al. A novel nicotinic acetylcholine receptor subtype in basal forebrain cholinergic neurons with high sensitivity to amyloid peptides. J Neurosci 29(4): 918-929 (2009).
29. Selkoe DJ. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res 192(1): 106-113 (2008).
30. Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol 572(Pt 2): 477-492 (2006).
31. Bach ME, Barad M, Son H, Zhuo M, Lu YF, Shih R, et al. Age-related defects in spatial memory are correlated with defects in the late phase of hippocampal long-term potentiation in vitro and are attenuated by drugs that enhance the cAMP signaling pathway. Proc Natl Acad Sci USA 96(9): 5280-5285 (1999).
32. Barnes CA, Rao G, Orr G. Age-related decrease in the Schaffer collateral-evoked EPSP in awake, freely behaving rats. Neural Plast 7(3): 167-178 (2000).
33. Vreugdenhil M, Toescu EC. Age-dependent reduction of gamma oscillations in the mouse hippocampus in vitro. Neuroscience 132(4): 1151-1157 (2005).
34. Klein WL. Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem Int 41(5): 345-352 (2002).
35. Vilchis-Landeros MM, Montiel JL, Mendoza V, Mendoza-Hernandez G, Lopez-Casillas F. Recombinant soluble betaglycan is a potent and isoform-selective transforming growth factor-beta neutralizing agent. Biochem J 355(Pt 1): 215-222 (2001).
36. Lemus-Aguilar I, Bargas J, Tecuapetla F, Galárraga E, Carrillo- Reid L. Diseño modular de instrumentación virtual para la manipulación y el análisis de señales electrofisiológicas. Rev Mex Ing Biomed 27: 82-92 (2006).
37. Peña F, Alavez-Perez N. Epileptiform activity induced by pharma- cologic reduction of M-current in the developing hippocampus in vitro. Epilepsia 47(1): 47-54 (2006).
38. Khazipov R, Leinekugel X, Khalilov I, Gaiarsa JL, Ben-Ari Y. Synchronization of GABAergic interneuronal network in CA3 sub- field of neonatal rat hippocampal slices. J Physiol 498 (Pt 3): 763-772 (1997).
39. Selkoe DJ. Physiological production of the beta-amyloid protein and the mechanism of Alzheimer's disease. Trends Neurosci 16(10): 403-409 (1993).
40. Buzsaki G, Draguhn A. Neuronal oscillations in cortical networks. Science 304(5679): 1926-1929 (2004).
41. Engel AK, Fries P, Singer W. Dynamic predictions: oscillations and synchrony in top-down processing. Nat Rev Neurosci 2(10): 704-716 (2001).
42. Traub RD, Jefferys JG, Whittington MA. Functionally relevant and functionally disruptive (epileptic) synchronized oscillations in brain slices. Adv Neurol 79: 709-724 (1999).
43. Hughes JR, Shanmugham S, Wetzel LC, Bellur S, Hughes CA. The relationship between EEG changes and cognitive functions in de- mentia: a study in a VA population. Clin Electroencephalogr 20(2): 77-85 (1989).
44. Ihl R, Dierks T, Martin EM, Froolich L, Maurer K. Topography of the maximum of the amplitude of EEG frequency bands in dementia of the Alzheimer type. Biol Psychiatry 39(5): 319-325 (1996).
45. Kowalski JW, Gawel M, Pfeffer A, Barcikowska M. The diagnostic value of EEG in Alzheimer disease: correlation with the severity of mental impairment. J Clin Neurophysiol 18(6): 570-575 (2001).
46. Nobili F, Copello F, Vitali P, Prastaro T, Carozzo S, Perego G, et al. Timing of disease progression by quantitative EEG in Alzheimer' s patients. J Clin Neurophysiol 16(6): 566-573 (1999).
47. Schreiter-Gasser U, Gasser T, Ziegler P. Quantitative EEG analysis in early onset Alzheimer's disease: correlations with severity, clinical characteristics, visual EEG and CCT. Electroencephalogr Clin Neurophysiol 90(4): 267-272 (1994).
48. Busciglio J, Andersen JK, Schipper HM, Gilad GM, McCarty R, Marzatico F, et al. Stress, aging, and neurodegenerative disorders. Molecular mechanisms. Ann NY Acad Sci 851: 429-443 (1998).
49. Chen QS, Wei WZ, Shimahara T, Xie CW. Alzheimer amyloid beta-peptide inhibits the late phase of long-term potentiation through calcineurin-dependent mechanisms in the hippocampal dentate gyrus. Neurobiol Learn Mem 77(3): 354-371 (2002).
50. Araki T, Kato H, Shuto K, Itoyama Y. Age-related changes in [3H] nimodipine and [3H] rolipram binding in the rat brain. J Pharm Pharmacol 49(3): 310-314 (1997).
51. Thibault O, Landfield PW. Increase in single L-type calcium channels in hippocampal neurons during aging. Science 272(5264): 1017-1020 (1996).
52. Rosenzweig ES, Barnes CA. Impact of aging on hippocampal function: plasticity, network dynamics, and cognition. Prog Neurobiol 69(3): 143-179 (2003).
53. Rosenzweig ES, Rao G, McNaughton BL, Barnes CA. Role of temporal summation in age-related long-term potentiation- induction deficits. Hippocampus 7(5): 549-558 (1997).
54. Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, et al. APP processing and synaptic function. Neuron 37(6): 925-937 (2003).
55. Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, et al. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci 24(45): 10191-10200 (2004).
56. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science 298(5594): 789-791 (2002).
57. Selkoe DJ, Podlisny MB. Deciphering the genetic basis of Alzheimer's disease. Annu Rev Genomics Hum Genet 3: 67-99 (2002).
58. Small DH, Mok SS, Bornstein JC. Alzheimer's disease and Abeta toxicity: from top to bottom. Nat Rev Neurosci 2(8): 595-598 (2001).
59. Kuo YM, Emmerling MR, Vigo-Pelfrey C, Kasunic TC, Kirkpatrick JB, Murdoch GH, et al. Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem 271(8): 4077-4081 (1996).
60. Chong YH, Shin YJ, Lee EO, Kayed R, Glabe CG, Tenner AJ. ERK1/2 activation mediates Abeta oligomer-induced neurotoxicity via caspase-3 activation and tau cleavage in rat organotypic hippo- campal slice cultures. J Biol Chem 281(29): 20315-20325 (2006).
61. Costantini C, Della-Bianca V, Formaggio E, Chiamulera C, Montresor A, Rossi F. The expression of p75 neurotrophin receptor protects against the neurotoxicity of soluble oligomers of beta- amyloid. Exp Cell Res 311(1): 126-134 (2005).
62. Deshpande A, Kawai H, Metherate R, Glabe CG, Busciglio J. A role for synaptic zinc in activity-dependent Abeta oligomer formation and accumulation at excitatory synapses. J Neurosci 29(13): 4004-4015 (2009).
63. Kim HJ, Chae SC, Lee DK, Chromy B, Lee SC, Park YC, et al. Selective neuronal degeneration induced by soluble oligomeric amyloid beta protein. FASEB J 17(1): 118-120 (2003).
64. Sturchler E, Galichet A, Weibel M, Leclerc E, Heizmann CW. Site- specific blockade of RAGE-Vd prevents amyloid-beta oligomer neurotoxicity. J Neurosci 28(20): 5149-5158 (2008).
65. Calixto E, Lopez-Colome AM, Casasola C, Montiel T, Bargas J, Brailowsky S. Neocortical hyperexcitability after GABA with- drawal in vitro. Epilepsy Res 39(1): 13-26 (2000).
66. Casasola C, Bargas J, Arias-Montano JA, Calixto E, Montiel T, Galarraga E, et al. Hippocampal hyperexcitability induced by GABA withdrawal is due to down-regulation of GABA(A) receptors. Epilepsy Res 47(3): 257-271 (2001).
67. Casasola C, Montiel T, Calixto E, Brailowsky S. Hyperexcitability induced by GABA withdrawal facilitates hippocampal long-term potentiation. Neuroscience 126(1): 163-171 (2004).
68. Garcia-Ugalde G, Galarraga E, Bargas J, Brailowsky S. Hyperex- citability of hippocampal CA1 region in brain slices after GABA withdrawal. Neurosci Lett 147(2): 229-232 (1992).
69. Drdla R, Gassner M, Gingl E, Sandkuhler J. Induction of synaptic long-term potentiation after opioid withdrawal. Science 325(5937): 207-210 (2009).
70. Bohme GA, Bon C, Stutzmann JM, Doble A, Blanchard JC. Possible involvement of nitric oxide in long-term potentiation. Eur J Pharmacol 199(3): 379-381 (1991).
71. Bon C, Bohme GA, Doble A, Stutzmann JM, Blanchard JC. A role for nitric oxide in long-term potentiation. Eur J Neurosci 4(5): 420-424 (1992).
72. Bon CL, Garthwaite J. Nitric oxide-induced potentiation of CA1 hippocampal synaptic transmission during baseline stimulation is strictly frequency-dependent. Neuropharmacology 40(4): 501-507 (2001).
73. Doolette DJ, Kerr DI. Hyperexcitability in CA1 of the rat hippo- campal slice following hypoxia or adenosine. Brain Res 677(1): 127-137 (1995).
74. Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 55(5): 697-711 (2007).
75. Palop JJ, Mucke L. Synaptic depression and aberrant excitatory network activity in Alzheimer's disease: Two Faces of the Same Coin? Neuromolecular Med 12(1): 48-55 (2010).
76. Palop JJ, Mucke L. Epilepsy and cognitive impairments in Alzheimer disease. Arch Neurol 66(4): 435-440 (2009).
77. Brown JT, Richardson JC, Collingridge GL, Randall AD, Davies CH. Synaptic transmission and synchronous activity is disrupted in hippocampal slices taken from aged TAS10 mice. Hippocampus 15(1): 110-117 (2005).
78. Ben-Ari Y, Gaiarsa JL, Tyzio R, Khazipov R. GABA: a pioneer transmitter that excites immature neurons and generates primitive oscillations. Physiol Rev 87(4): 1215-1284 (2007).
79. Cullen WK, Suh YH, Anwyl R, Rowan MJ. Block of LTP in rat hippocampus in vivo by beta-amyloid precursor protein fragments. Neuroreport 8(15): 3213-3217 (1997).
80. Fitzjohn SM, Morton RA, Kuenzi F, Rosahl TW, Shearman M, Lewis H, et al. Age-related impairment of synaptic transmission but normal long-term potentiation in transgenic mice that over express the human APP695SWE mutant form of amyloid precursor protein. J Neurosci 21(13): 4691-4698 (2001).
81. Klyubin I, Walsh DM, Cullen WK, Fadeeva JV, Anwyl R, Selkoe DJ, et al. Soluble Arctic amyloid beta protein inhibits hippocampal long-term potentiation in vivo. Eur J Neurosci 19(10): 2839-2846 (2004).
82. Rowan MJ, Klyubin I, Wang Q, Hu NW, Anwyl R. Synaptic memory mechanisms: Alzheimer's disease amyloid beta-peptide- induced dysfunction. Biochem Soc Trans 35(Pt 5): 1219-1223 (2007).
83. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14(8): 837-842 (2008).
84. Almeida CG, Tampellini D, Takahashi RH, Greengard P, Lin MT, Snyder EM, et al. Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses. Neurobiol Dis 20(2): 187-198 (2005).
85. Cullen WK, Wu J, Anwyl R, Rowan MJ. beta-Amyloid produces a delayed NMDA receptor-dependent reduction in synaptic transmission in rat hippocampus. Neuroreport 8(1): 87-92 (1996).
86. Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, Sisodia S, et al. AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron 52(5): 831-843 (2006).
87. Lanz TA, Carter DB, Merchant KM. Dendritic spine loss in the hippocampus of young PDAPP and Tg2576 mice and its prevention by the ApoE2 genotype. Neurobiol Dis 13(3): 246-253 (2003).
88. Roselli F, Tirard M, Lu J, Hutzler P, Lamberti P, Livrea P, et al. Soluble beta-amyloid1-40 induces NMDA-dependent degradation of postsynaptic density-95 at glutamatergic synapses. J Neurosci 25(48): 11061-11070 (2005).
89. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid-beta pro- tein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 27(11): 2866-2875 (2007).
90. Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, et al. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 8(8): 1051-1058 (2005).
91. Spires TL, Meyer-Luehmann M, Stern EA, McLean PJ, Skoch J, Nguyen PT, et al. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J Neurosci 25(31): 7278-7287 (2005).